In vitro comparison of Pulmicort Respules™ with Clenil® pro aerosol in combination with three nebulisersSource: Eur Respir J 2002; 20: Suppl. 38, 41s Year: 2002
Comparison of two budesonide powder inhalers, Giona Easyhaler® and Pulmicort Turbuhaler® in steroid-naive asthmatic patients Source: Eur Respir J 2001; 18: Suppl. 33, 100s Year: 2001
Pharmacokinetic and pharmacodinamic effect of AeroChamber Plus spacer on the Extrafine beclometasone dipropionate plus formoterol combination (200/6 µg) Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Comparability of formoterol dry powder (DPI) and metered dose inhalers (MDI) in asthma Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005
Comparison of a dry powder inhaler (DPI) to a pressurized metered-dose inhaler (pMDI) formulation of extra fine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) in patients with COPD: The TRI-D study. Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020
Aerodynamic characteristics of dry powder inhaler (DPI) single-dose combination of budesonide with formoterol in vitro study validation Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012
Flutide™ Diskus™ less consistent than Pulmicort® Turbuhaler® with respect to in vitro fine particle dose proportionality Source: Eur Respir J 2001; 18: Suppl. 33, 157s Year: 2001
Pharmacokinetics and pharmacodynamics of beclomethasone dipropionate and formoterol combination after inhalation using a new dry powder inhaler Source: Eur Respir J 2007; 30: Suppl. 51, 350s Year: 2007
Lung deposition of formoterol in COPD patients: comparison of formoterol HFA pMDI, and formoterol dry powder inhaler Source: Eur Respir J 2007; 30: Suppl. 51, 100s Year: 2007
Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (MDI) in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
Beclometasone/formoterol administered via extrafine dry powder inhaler in controlled asthmatic patients: Comparison with pMDI and beclometasone monotherapy Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012
Physicochemical compatibility of ipratropium, albuterol and fluticasone nebulizer solutions Source: Eur Respir J 2006; 28: Suppl. 50, 211s Year: 2006
In vitro comparison of aerosol characteristics of HFA albuterol (salbutamol) pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs) Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Does Clickhaler match the Turbuhaler for efficacy of inhaled budesonide? Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
In vitro lung deposition of fluticasone propionate/formoterol (FP/FORM) pressurized metered dose inhaler (pMDI) with different inhalation profiles Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014
Once-daily budesonide: clinical equivalence of two dry powder inhalers (DPIs) Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005
Comparison of the safety relating to paradoxical bronchoconstriction of ipratropium bromide (IB) alone or combined with fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (CFC-MDI) in Source: Eur Respir J 2002; 20: Suppl. 38, 246s Year: 2002
Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017
Dose linearity of beclometasone dipropionate (BDP) in a pMDI BDP plus formoterol fixed combination Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II Year: 2010
Salmeterol metered dose inhaler (MDI) propelled by hydrofluoroalkane (HFA) is non-inferior to salmeterol chlorofluorocarbon (CFC) propelled MDI in paediatic patients with persistent asthma Source: Eur Respir J 2004; 24: Suppl. 48, 583s Year: 2004